New York Codes, Rules and Regulations › Title 9 - EXECUTIVE DEPARTMENT › Subtitle T - New York State Gaming Commission › Chapter I - Division of Horse Racing and Pari-Mutuel Wagering › Subchapter A - Thoroughbred Racing › Article 1 - Rules of Racing › Part 4043 - Drugs Prohibited and Other Prohibitions › Section 4043.12 - Prohibited substances and methods

Current through Register Vol. 46, No. 28, July 10, 2024
(a) The substances and methods listed in the
						ARCI prohibited list are prohibited, may not be used at any place or time and
						may not be possessed on the premises of any racing or training facility under
						the jurisdiction of the commission except as a restricted therapeutic use. ARCI
						prohibited list means the "Prohibited List" annexed to Model Rule ARCI-011-015
						Version 7.0 (approved December 9, 2016) of the Association of Racing
						Commissioners International, Inc., 1510 Newtown Pike, Suite 210, Lexington, KY
						40511, which is hereby incorporated by reference. Such Uniform Rules of Racing
						are available for public inspection at the New York State Gaming Commission
						located at 354 Broadway, Schenectady, NY 12305 and at the Department of State,
						99 Washington Avenue, Albany, NY 12231.
(b) Restricted therapeutic use. A limited
						number of medications and methods listed in the ARCI Prohibited List shall be
						exempted when the administration occurs in compliance with the required
						conditions for restricted therapeutic use set forth in the table in this
						subdivision, whose columns shall mean:
(1)
						Report when sampled means the administration of the substance must be reported
						to the commission when the horse is next sampled, if the horse is sampled
						within 24 hours after the administration;
(2) Pre-File treatment plan means that if the
						commission where the horse is located requires the filing of treatment plans,
						then a treatment plan for the substance must be filed by the time of
						administration in a manner approved by such commission;
(3) Written approval from commission means
						the commission has granted written approval of a written treatment plan before
						the administration of the substance, including as may be required by the
						column's footnotes;
(4) Emergency
						use (report) means the substance had to be administered due to an acute
						emergency involving the life or health of the horse, provided the emergency use
						is reported to the commission as soon as practicable after the treatment
						occurs;
(5) Prescribed by
						veterinarian means the substance has been prescribed by an attending
						veterinarian in a manner consistent with the standards and procedures described
						in section 4043.16 of this Article and
						recorded in a manner consistent with the requirements of section
						4012.4 of this Article;
(6) Report treatment means the treatment must
						be reported to the commission by the trainer at the time of administration to
						provide the commission with information for the veterinarian's list. The
						trainer may delegate this responsibility to the treating veterinarian, who
						shall make the report when so designated; and
(7) Other limitations means additional
						requirements that apply, such as a substance may be used in only fillies or
						mares or a horse that is administered a substance shall be reported immediately
						to the commission and placed on the veterinarian's list for a specific minimum
						period of time.
Required Conditions for Restricted Therapeutic
						  Use
Prohibited substance
Report when sampled
Prefile treatment plan
Written approval from
										commission
Emergency use (report)
Prescribed by veterinarian
Report treatment
Other limitations
adrenocorticotropichormone
										(ACTH)
x
x
-
albuterol
x
-
altrenogest
x
fillies/ mares only
autol ogous conditioned plasma
										(IRAP)
x
x
-
blood replacements
x
x
x
-
boldenone
x
x
x
6-month vet list
clenbuterol
x
x
x
x
Vet list
chorionic gonadotropin
x
x-1
x
x
60-day vet list
furosemide
x
x
-
luteinizing hor mone
x
x-1
x
x
60-day vet list
mesenchymal stem cells
x
x
x
-
nandrolone
x
x
x
6-month vet list
nucleic polymer transfers
x
x
x
x
-
platelet rich plasma (PRP)
x
x
-
stanozolol
x
x
x
6-month vet list
S0 (not FDA- approved)
x-2
x
-
testosterone
x
x
x
6-month vet list
thyroxine (T4)
x
x-3
x
-
trichlormex thiazide
x
x
-
other diuretics
x
x
x
-
Notes:
x-1:
						The approved treatment plan must show a specific treatment of a specific
						individual horse for an undescended testicle condition.
x-2: The approved treatment plan must show:
(A) the substance has a generally accepted
						veterinary use;
(B) the treatment
						provides a significant health benefit for the horse;
(C) there is no reasonable therapeutic
						alternative; and
(D) the use of the
						substance is highly unlikely to produce any additional enhancement of
						performance beyond what might be anticipated by a return to the horse's normal
						state of health, not exceeding the level of performance of the horse prior to
						the onset of the horse's medical condition.
x-3: The approved treatment plan must show:
(A) the thyroxine is prescribed to a specific
						individual horse for a specific period of time;
(B) the diagnosis and basis for prescribing
						such drug, the dosage, and the estimated last administration date; and
(C) that any container of such
						drug on licensed premises shall be labeled with the foregoing information and
						contain no more thyroxine than for the treatment of the specific individual
						horse, as prescribed.